BioPharma Resources

Free tools

BioPharma Resources

Public FDA, Medicare, clinical trial and research data on prescription drugs and biologics, organized the way clinicians, payers and investors look at it: by drug, therapeutic area and company.

Look up any drug, biologic or condition

5,899 NDAs and BLAs (3,248 still marketed). Search a drug for its label, approvals, trials, adverse events and Medicare spending, or a condition for every drug approved to treat it.

Popular conditions: Type 2 diabetes · Obesity · Migraine · Breast cancer · Multiple sclerosis · Psoriasis · all conditions

Or browse by area: Oncology · Hematology and blood cancers · Cardiovascular and metabolic · Neurology · Psychiatry · Immunology and inflammation · Infectious disease and vaccines · Respiratory

Drug Search

Any FDA-approved brand-name drug or biologic, with its label, approval history, trials, adverse events, Medicare spending and an AI brief.

Source: FDA, CMS, ClinicalTrials.gov, PubMed

Drugs by Condition

Every brand-name drug and biologic FDA has approved for a disease, from diabetes to rare conditions, grouped by drug class.

Source: FDA labels, Drugs@FDA

Drug Pipeline

Thousands of investigational drugs in Phase 2 and 3 trials, with code names merged, sponsors, conditions and trials.

Source: ClinicalTrials.gov

Approval Tracker

Every original NDA and BLA approval and new-use supplement since 2000, with novel drugs and expedited programs flagged.

Source: Drugs@FDA, CDER

Expedited Programs

Breakthrough therapy, accelerated approval, priority review and orphan approvals, by year and company.

Source: FDA CDER

PDUFA Calendar

Upcoming FDA action dates and advisory committee meetings, compiled weekly from announcements with a source for every row.

Source: Company and FDA announcements (AI-compiled)

FAERS Monitor

Adverse event reports for any drug: most reported reactions, seriousness, trend by year and disproportionality signals.

Source: FDA FAERS (openFDA)

Medicare Drug Spending

What Medicare Part D and Part B spend on each drug, per claim, per beneficiary and per unit, 2020 to 2024.

Source: CMS

Drug Trial Radar

Drug and biologic trials by therapeutic area, phase, sponsor, status and distance from you.

Source: ClinicalTrials.gov

Company Pipelines

Each sponsor's approved drugs, expedited approvals and registered trials by phase.

Source: Drugs@FDA, ClinicalTrials.gov

Literature Search

Clinical research across PubMed, Europe PMC and OpenAlex in one search, with a link to Google Scholar.

Source: PubMed, Europe PMC, OpenAlex

Drug News

Trade press, FDA announcements, new approvals and Class I recalls, with a daily digest.

Source: BioPharma Dive, STAT, FDA

Newest novel approvals

All novel approvals
  • Klygefa (Gefurulimab) · Alexion PharmOrphanNov 13, 2026
  • Pimjetmi (Pimicotinib) · Emd SeronoNov 10, 2026
  • Sunharbo (Asundexian) · Bayer HealthcarePriority reviewNov 9, 2026
  • Hibsago (Bepirovirsen Sodium) · GlaxosmithklinePriority reviewOct 20, 2026
  • Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectPriority reviewOct 9, 2026
  • Emcitate (Tiratricol) · Rare ThyroidPriority reviewOrphanSep 28, 2026

Browse by therapeutic area

Each area pulls together its recent approvals, trials by phase and news.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.